Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Recurrence × trametinib × Clear all

Status

Sponsor Class

OTHER 3 INDUSTRY 1

Study Type

Observational 1

Sponsor

Conditions

Melanoma 32 Neoplasms 27 Carcinoma, Non-Small-Cell Lung 15 Colorectal Neoplasms 9 Pancreatic Neoplasms 4 Neoplasm Metastasis 4 Glioma 4 Triple Negative Breast Neoplasms 3 Skin Neoplasms 3 Lung Neoplasms 3 Thyroid Neoplasms 2 Rectal Neoplasms 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Oligodendroglioma 2 Neurocytoma 2 Glioblastoma 2 Ganglioneuroma 2 Ganglioglioma 2 Colonic Neoplasms 2 Brain Neoplasms 2 Biliary Tract Neoplasms 2 Astrocytoma 2 Adenocarcinoma of Lung 2 Uveal Melanoma 1 Thyroid Carcinoma, Anaplastic 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer 1

Interventions

Dexamethasone 46 Cyclophosphamide 28 Lenalidomide 27 pomalidomide 24 Rituximab 23 venetoclax 22 fludarabine 21 Bortezomib 20 Paclitaxel 18 Gemcitabine 18 carfilzomib 16 Carboplatin 15 pembrolizumab 14 Cisplatin 14 daratumumab 13 Docetaxel 12 Calcium Dobesilate 12 Cytarabine 11 Azacitidine 11 obinutuzumab 10 Nivolumab 10 Bevacizumab 10 tisagenlecleucel 9 ibrutinib 9 durvalumab 8 blinatumomab 8 Injections 8 Cetuximab 8 zanubrutinib 7 selinexor 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06262919 2025-12-30

Special Drug Use-results Surveillance of Tafinlar/Mekinist

Novartis

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡